Items Tagged ‘pharmacogenomics’
September 8, 2021
Genetic variants influence migraine treatment response, according to new Mayo study
By Susan Murphy 
Migraines affect nearly 40 million people in the U.S. Yet pinpointing an effective prophylactic medication ― the most commonly prescribed drugs for people diagnosed with migraines ― remains a long and complex process. Patients often cycle through medications for weeks or months until achieving a therapeutic response. Now after years of slow progress in migraine therapies […]
Tags: Center for Individualized Medicine, Fred Cutrer, genetics, migraine, neurology, personalized medicine, pharmacogenomics, Richard Weinshilboum
April 1, 2021
Research News Roundup — Q1 2021
The first quarter of 2021 saw furthered understanding the SARS-CoV-2 virus and related COVID-19 viral infection. In addition, a number of advances occurred including in genetics knowledge, cancer treatments, as well as interinstitutional collaborations, expanding programs and recognition of some of the most exceptional contributions of current and former Mayo Clinic clinician-scientists. Mayo Clinic and ASU […]
Tags: Arizona State University, biomarkers, brain cancer, BRCA2, breast cancer, chemotherapy, COVID-19, David Holmes Jr., diversity, education, Fergus Couch, gene variant
September 3, 2020
By Advancing the Science contributor
Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement― nonsurgical procedures to improve blood flow to the heart ― are typically prescribed anti-platelet therapy to avoid blood clots that can lead to a heart attack or stroke. New research from the international TAILOR-PCI trial, the largest pharmacogenetics clinical trial in cardiology, suggests that genetic testing could […]
Tags: angioplasty, antiplatelet, cardiology, Center for Individualized Medicine, Charanjit Rihal, clinical trials, coronary artery disease, gene variant, genetics, heart disease, Kent Bailey, Michael Farkouh
November 21, 2019
Getting to the heart of cancer treatment side effects
By Advancing the Science contributor
By Sara Nick Cancer care has come a long way in recent decades, with some types achieving survival rates of 90% or more. But longer survival times have introduced new consequences: namely, common cancer treatments can lead to an increased risk of serious heart problems later on. “Chemotherapy and radiation are lifesaving, but we’re playing […]
Tags: basic science, biobank, cardiology, Carolyn Landolfo, collaboration, DeLisa Fairweather, discovery research, genetic testing, genetics, Jordan Ray, Mayo Clinic Cancer Center, Nadine Norton
October 14, 2019
BEAUTY Update: Progress in breast cancer research
By Advancing the Science contributor
By Barbara J. Toman Chemotherapy is a standard breast cancer treatment, used for aggressive biology breast cancer to shrink tumors in the breast and lymph nodes before surgery, assess response and destroy any undetected cancer cells elsewhere in the patient. But some breast tumors don’t respond well to chemotherapy, putting patients at high risk of […]
Tags: breast cancer, cancer, Center for Individualized Medicine, chemotherapy, clinical trials, genetics, genomics, individualized medicine, Judy Boughey, Liewei Wang, Matthew Goetz, Mayo Clinic Cancer Center
September 4, 2019
Mayo experts provide insights into how genes affect medication response
By Advancing the Science contributor
By Sharon Rosen Pharmacogenomics – how a person’s genes affect medication response – is touching virtually every area of medical care. Findings from the Mayo Clinic RIGHT study (Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment) showed that 99% of participants had at least one genetic variant that may affect their response […]
Tags: breast cancer, cancer, cancer genomics, Center for Individualized Medicine, Eric Matey, Lauren Cornell, mental health, Michael Shuh, neurology, opioids, pharmacogenomics, pharmacy
January 22, 2019
Pharmacogenomics: finding the right drug, dose for cancer therapy
By Advancing the Science contributor
By Sharon Rosen Each year, nearly 300,000 patients receive the lifesaving chemotherapy 5-fluorouracil (5-FU) to treat many types of cancer, including colorectal, breast, bowel, skin, pancreatic, and esophageal cancer. While it can be an effective treatment, it doesn’t work for everyone. In fact, up to 30 percent of those who receive the standard dose can […]
Tags: cancer, Center for Individualized Medicine, individualized medicine, Mayo Clinic Cancer Center, personalized medicine, pharmacogenomics, Robert Diasio
January 17, 2019
RIGHT 10K: Blazing a trail to health care’s future
Article by Barbara Toman This article originally appeared on the Center for Individualized Medicine blog Mayo Clinic’s Center for Individualized Medicine (CIM) is nearing the finish line of the first stage of its unique RIGHT 10K study—an effort that doesn’t involve running shoes but nevertheless is paving the way to prescribing medications matched to a […]
Tags: Center for Individualized Medicine, Eric Matey, genetics, Jessica Wright, pharmacogenomics, RIGHT 10K study
December 10, 2018
Novel data-driven approach for precision medicine
Thousands of patients’ tumors have been sequenced in the past decade, yielding a rich source of data on the changes associated with the cancer development and treatment response. However, there are no validated methods that are used in the clinic to select the best therapy. Today, Mayo Clinic researchers report an omics-guided (comprehensive) drug prioritization […]
Tags: cancer, Center for Individualized Medicine, Judy Boughey, Krishna Rani Kalari, Liewei Wang, Matthew Goetz, personalized medicine, pharmacogenomics
November 6, 2018
This article originally appeared on the Center for Individualized Medicine blog on Oct. 23, 2018. Mayo Clinic research is bringing together knowledge of psychiatry, genetics, metabolomics, pharmacogenomics and artificial intelligence to seek biological markers associated with alcohol use disorder and treatment response. Finding the molecular drivers of alcohol use disorder commonly known as alcoholism, could […]
Tags: Center for Individualized Medicine, Mark Frye, pharmacogenomics, Richard Weinshilboum